Novum Jus
April 29, 2026
Francisco Javier Esteban Guinea
En nuestra investigación comenzaremos por definir qué es la ayahuasca, cuáles son sus efectos y qué riesgos produce su consumo para la salud pública. El empleo de la ayahuasca en rituales chamánicos, religiosos, psicoterapéuticos o de autoconocimiento se ha expandido en los últimos decenios por casi todo el planeta. Los diversos usos del brebaje psicoactivo plantean retos a los diferentes...
Journal of Psychoactive Drugs
April 23, 2026
Brayan Jonas Mano-Sousa, Maria Clara Gama Fontes, Ana Clara Anacleto Gonçalves et al.
Suicide, particularly in treatment-resistant depression (TRD), remains a pressing global health issue, with over 700,000 annual deaths. Existing treatments often have limited efficacy and delayed onset, creating a need for rapid-acting interventions. Ayahuasca, a traditional Amazonian psychedelic, has shown potential for rapidly reducing suicidal ideation. Our systematic review evaluated the...
Psychedelics
April 20, 2026
José Carlos Bouso, Óscar Andión, Jordi Cantillo et al.
The Symmetrical Global Mental Health (Sym-GMH) paradigm proposes a reciprocal integration between traditional and Western medical systems. This prospective, longitudinal study evaluates the psychological outcomes of 264 Western participants who engaged in Shipibo-led ayahuasca retreats at the Temple of the Way of Light in the Peruvian Amazon. Over a 12-month period, participants completed...
Psychopharmacology
April 14, 2026
Guilherme Lodetti, Antonio Inserra, Henrique Redivo et al.
BACKGROUND: Chronic stress is a risk factor for the development of anxiety, depression, and comorbid systemic conditions. Ayahuasca (AYA) has been used for hundreds of years and it elicits antidepressant and anxiolytic effects. However, it remains unknown whether AYA elicits a behavioral and biochemical protective effect in chronic stress. AIM OF THE STUDY: Therefore, we evaluated the...
Zenodo (CERN European Organization for Nuclear Research)
April 3, 2026
Espinoza Patricio
This article reviews the current clinical evidence for psilocybin and ayahuasca as therapeutic agents, examining data from over 134 registered clinical trials and key publications in the New England Journal of Medicine, JAMA, JAMA Psychiatry, and Nature Neuroscience. The review addresses four dimensions: (1) the state of clinical evidence for psilocybin and ayahuasca in major depression and...
Revista Políticas Públicas & Cidades
April 2, 2026
Adrian Santos de Souza, Endiamara Magda Segala Shigemori, Celso Ferraz Bett
A depressão é uma das principais causas de incapacidade no mundo, e suas abordagens terapêuticas convencionais, embora eficazes para muitos pacientes, ainda apresentam limitações significativas, como início tardio dos efeitos e resistência ao tratamento. Nesse contexto, destaca-se a hoasca, também conhecida como ayahuasca, uma infusão amazônica tradicional composta por Banisteriopsis caapi e...